Modality
ADC
MOA
JAK1i
Target
Aβ
Pathway
Autophagy
SCD
Development Pipeline
Preclinical
~Mar 2013
→ ~Jun 2014
Phase 1
~Sep 2014
→ ~Dec 2015
Phase 2
~Mar 2016
→ ~Jun 2017
Phase 3
Sep 2017
→ May 2026
Phase 3Current
NCT03722260
226 pts·SCD
2022-02→2025-05·Terminated
NCT06854353
447 pts·SCD
2018-03→2026-05·Completed
NCT08472845
25 pts·SCD
2017-09→TBD·Recruiting
+1 more trial
735 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-03-211.0y agoPh3 Readout· SCD
2025-05-1211mo agoPh3 Readout· SCD
2026-05-172mo awayPh3 Readout· SCD
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P3
Recruit…
P3
Recruit…
P3
Complet…
P3
Termina…
Catalysts
Ph3 Readout
2025-03-21 · 1.0y ago
SCD
Ph3 Readout
2025-05-12 · 11mo ago
SCD
Ph3 Readout
2026-05-17 · 2mo away
SCD
RecruitingCompletedTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03722260 | Phase 3 | SCD | Terminated | 226 | FEV1 |
| NCT06854353 | Phase 3 | SCD | Completed | 447 | NT-proBNP |
| NCT08472845 | Phase 3 | SCD | Recruiting | 25 | EASI-75 |
| NCT03123272 | Phase 3 | SCD | Recruiting | 37 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA |